SCOPUS 정보 검색 플랫폼

Volumn 19, Issue 11, 2009, Pages 1501-1519

PDE4 inhibitors: A review of current developments (2005 – 2009)

(3) Pagès, Lluís a Gavaldà, Amadeu a Lehner, Martin d a

a 08980 Sant Feliu de Llobregat ^* (Spain)

Author keywords

asthma; atopic dermatitis; chronic obstructive pulmonary disease; inhalation; PDE4; psoriasis; respiratory disease; rheumatoid arthritis

Indexed keywords

AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROFLUMILAST;

ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; INFLAMMATION; NEUROLOGIC DISEASE; PATENT; PATHOPHYSIOLOGY; REVIEW;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DRUG DESIGN; HUMANS; INFLAMMATION; NERVOUS SYSTEM DISEASES; PATENTS AS TOPIC; PHOSPHODIESTERASE INHIBITORS;

EID: 74949133079 PISSN: 13543776 EISSN: 17447674 Source Type: Journal
DOI: 10.1517/13543770903313753 Document Type: Article

Times cited : (89)

References (200)

1
- 27344449614
- Keynote review: phosphodiesterase-4 as a therapeutic target
- Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 15: 1503 - 19
- (2005) Drug Discov Today , vol.15 , pp. 1503-1519
- Houslay, M.D.¹ Schafer, P.² Zhang, K.Y.³

2
- 24944520099
- Phosphodiesterase inhibitors for cognitive enhancement
- Rose GM, Hopper A, De Vivo, Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005; 11: 3329 - 34
- (2005) Curr Pharm Des , vol.11 , pp. 3329-3334
- Rose, G.M.¹ Hopper, A.² De, V.³

3
- 33645229167
- Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?
- Ghavami A, Hirst WD, Novak TJ. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit? Drugs RD 2006; 7: 63 - 71
- (2006) Drugs RD , vol.7 , pp. 63-71
- Ghavami, A.¹ Hirst, W.D.² Novak, T.J.³

4
- 28844485982
- Phosphodiesterase-4 as a potential drug target
- Zhang KY, Ibrahim PN, Gillette S, Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 2005; 9: 1283 - 305
- (2005) Expert Opin Ther Targets , vol.9 , pp. 1283-1305
- Zhang, K.Y.¹ Ibrahim, P.N.² Gillette, S.³

5
- 52949140176
- PDE4 inhibitors: current status
- Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155: 308 - 15
- (2008) Br J Pharmacol , vol.155 , pp. 308-315
- Spina, D.¹

6
- 34447310046
- Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
- Calverley PM, Sanchez-Toril F, McIvor A, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154 - 61
- (2007) Am J Respir Crit Care Med , vol.176 , pp. 154-161
- Calverley, P.M.¹ Sanchez-Toril, F.² McIvor, A.³

7
- 33144469314
- Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4
- Rennard SI, Schachter N, Strek M, Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006; 129: 56 - 66
- (2006) Chest , vol.129 , pp. 56-66
- Rennard, S.I.¹ Schachter, N.² Strek, M.³

8
- 0030925148
- Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases
- Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997; 9: 227 - 36
- (1997) Cell Signal , vol.9 , pp. 227-236
- Souness, J.E.¹ Rao, S.²

9
- 52949103280
- Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?
- Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008; 155: 288 - 90
- (2008) Br J Pharmacol , vol.155 , pp. 288-290
- Giembycz, M.A.¹

10
- 23744451716
- Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
- Rabe KF, Bateman ED, O'Donnell D, Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563 - 71
- (2005) Lancet , vol.366 , pp. 563-571
- Rabe, K.F.¹ Bateman, E.D.² O'Donnell, D.³

11
- 34447310046
- Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
- Calverley PM, Sanchez-Toril F, McIvor A, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154 - 61
- (2007) Am J Respir Crit Care Med , vol.176 , pp. 154-161
- Calverley, P.M.¹ Sanchez-Toril, F.² McIvor, A.³

12
- 85018891629
- (Press release 12.08.2008). Available from [Last accessed 8 July 2009]
- Nycomed confirms positive trend in third quarter 2008. (Press release 12.08.2008). Available from: http://www.nycomed.com/en/Menu/Media/News+releases/. [Last accessed 8 July 2009]

13
- 85018862615
- (Press release 08.05.2009). Available from [Last accessed 8 July 2009]
- Nycomed files European marketing authorisation application for Daxas® in COPD. (Press release 08.05.2009). Available from: http://www.nycomed.com/en/Menu/Media/News+releases/. [Last accessed 8 July 2009]

14
- 22744450101
- The pharmacological and safety profile of a novel selective phosphodiesterase-4 (PDE4) inhibitor:GRC-3886
- Vakkalanka SKVS, Balasubramaniam LA, Gharat LA, The pharmacological and safety profile of a novel selective phosphodiesterase-4 (PDE4) inhibitor:GRC-3886. Eur Respir J 2004; 24: 1391
- (2004) Eur Respir J , vol.24 , pp. 1391
- Vakkalanka, S.K.V.S.¹ Balasubramaniam, L.A.² Gharat, L.A.³

15
- 85018891158
- (Press release: 10.10.2008). Available from [Last accessed 8 July 2009]
- Phase II-b trials for Oglemilast(GRC 3886) in Asthma initiated.(Press release: 10.10.2008). Available from: http://www.glenmarkpharma.com/media/pdf/releases/Release-PhaseII-b_trials_for_Oglemilast_GRC_3886.pdf. [Last accessed 8 July 2009]

16
- 22744435196
- Inhibitors of PDE4: a review of recent patent literature
- Odingo JO. Inhibitors of PDE4: a review of recent patent literature. Expert Opin Ther Patents 2005; 15 (7): 773 - 87
- (2005) Expert Opin Ther Patents , vol.15 , Issue.7 , pp. 773-787
- Odingo, J.O.¹

17
- 85018926894
- Available from [Last accessed 13 July 2009]
- OX914–against COPD and asthma. Available from: http://www.orexo.com/ en/Portfolio/OX-914/. [Last accessed 13 July 2009]

18
- 85018887263
- Maximizing efficacy of phosphodiesterase 4 inhibitors for COPD and asthma
- London
- Shafer P. Maximizing efficacy of phosphodiesterase 4 inhibitors for COPD and asthma. SMI Conference on chronic obstructive pulmonary disorders, London; 2005
- (2005) SMI Conference on chronic obstructive pulmonary disorders
- Shafer, P.¹

19
- 44349161096
- An open-label, single-arm pilot study in paients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
- Gottlieb AB, Strober B, Krueger JG, An open-label, single-arm pilot study in paients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008; 24 (5): 1529 - 38
- (2008) Curr Med Res Opin , vol.24 , Issue.5 , pp. 1529-1538
- Gottlieb, A.B.¹ Strober, B.² Krueger, J.G.³

20
- 84860193460
- A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis
- Papp K, Zeldis J, Rohane P, A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis. J Am Acad Dermatol 2008; 58: AB3
- (2008) J Am Acad Dermatol , vol.58 , pp. AB3
- Papp, K.¹ Zeldis, J.² Rohane, P.³

21
- 85018895529
- A service of the US National Institutes of Health. Search of CC- 10004. Available from [Last accessed 13 July 2009]
- Clinical trials.gov. A service of the US National Institutes of Health. Search of CC- 10004. Available from: http://www.clinicaltrials.gov/ct2/results?term=cc-10004. [Last accessed 13 July 2009]

22
- 85018898444
- Available from [Last accessed 10 July 2009]
- Efficacy, safety and tolerability of MEM 1414 on allergen-induced late asthmatic response in steroid-free subjects with mild allergic asthma. Available from: http://www.controlled-trials.com/ISRCTN48047493. [Last accessed 10 July 2009]

23
- 85018908111
- Available from [Last accessed 13 July 2009]
- PDE-4 Inhibitor [GRC 4039] - Rheumatoid Arthritis, Inflammation. Available from: http://www.glenmarkpharma.com/research/clinical_02.html. [Last accessed 13 July 2009]

24
- 84894885403
- The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD
- Kuss H, Egerland U, Hoefgen N, The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD. Eur Resp J 2003; 22 (Suppl 45): P742
- (2003) Eur Resp J , vol.22 , pp. P742
- Kuss, H.¹ Egerland, U.² Hoefgen, N.³

25
- 85018912614
- Kuss H, Hoppmann J, Egerland U, ELB353, a new selective PDE4-inhibitor with a high safety margin and anti-inflammatory effects in rat and ferret lungs [abstract]. 7th World Congr Inflamm (August 20-24, Melbourne); 2005
- (2005) ELB353, a new selective PDE4-inhibitor with a high safety margin and anti-inflammatory effects in rat and ferret lungs [abstract]. 7th World Congr Inflamm (August 20-24, Melbourne)
- Kuss, H.¹ Hoppmann, J.² Egerland, U.³

26
- 85018899257
- Kronbach T. Discovery and development of subtype selective PD inhibitors in a 11-dimentional space. 3rd annual phosphodiesterases in drug discovery and development, Philadelphia; 2005
- (2005) Discovery and development of subtype selective PD inhibitors in a 11-dimentional space. 3rd annual phosphodiesterases in drug discovery and development, Philadelphia
- Kronbach, T.¹

27
- 85018872873
- Available from [Last accessed 8 July 2009]
- ELB353, an oral PDE4 inhibitor for COPD in clinical development. Available from: http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1315196&NewsItemYear=2009. [Last accessed 8 July 2009]

28
- 85018904611
- WO2005090345
- Altana Pharma AG. WO2005090345; 2005
- (2005)

29
- 85018934483
- WO2005012252
- Altana Pharma AG. WO2005012252; 2005
- (2005)

30
- 85018920758
- WO2005012253
- Altana Pharma AG. WO2005012253; 2005
- (2005)

31
- 85018885922
- WO2005077906
- Altana Pharma AG. WO2005077906; 2005
- (2005)

32
- 85018919022
- WO2005084104
- Altana Pharma AG. WO2005084104; 2005
- (2005)

33
- 85018920089
- WO2005085225
- Altana Pharma AG. WO2005085225; 2005
- (2005)

34
- 85018864804
- WO2005087744
- Altana Pharma AG. WO2005087744; 2005
- (2005)

35
- 85018890138
- WO2005087745
- Altana Pharma AG. WO2005087745; 2005
- (2005)

36
- 85018937623
- WO2005090311
- Altana Pharma AG. WO2005090311; 2005
- (2005)

37
- 85018929092
- WO2006082185
- Altana Pharma AG. WO2006082185; 2006
- (2006)

38
- 85018867942
- WO2006092417
- Altana Pharma AG. WO2006092417; 2006
- (2006)

39
- 85018878226
- WO2006092422
- Altana Pharma AG. WO2006092422; 2006
- (2006)

40
- 85018888694
- WO2006095009
- Altana Pharma AG. WO2006095009; 2006
- (2006)

41
- 85018869123
- WO2005023253
- Altana Pharma AG. WO2005023253; 2005
- (2005)

42
- 85018864973
- WO2005085203
- Altana Pharma AG. WO2005085203; 2005
- (2005)

43
- 85018930766
- WO2006027344
- Altana Pharma AG. WO2006027344; 2006
- (2006)

44
- 85018925420
- WO2006027345
- Altana Pharma AG. WO2006027345; 2006
- (2006)

45
- 85018877517
- WO2005075437
- Altana Pharma AG. WO2005075437; 2005
- (2005)

46
- 85018909111
- WO2005075456
- Altana Pharma AG. WO2005075456; 2005
- (2005)

47
- 85018916384
- WO2008138939
- Altana Pharma AG. WO2008138939; 2008
- (2008)

48
- 85018918486
- WO2005075457
- Altana Pharma AG. WO2005075457; 2005
- (2005)

49
- 85018892040
- WO2005082361
- Altana Pharma AG. WO2005082361; 2005
- (2005)

50
- 85018864009
- WO2006120176
- Altana Pharma AG. WO2006120176; 2006
- (2006)

51
- 85018895144
- WO2008003701
- Altana Pharma AG. WO2008003701; 2008
- (2008)

52
- 85018910372
- WO2006094933
- Altana Pharma AG. WO2006094933; 2006
- (2006)

53
- 85018868741
- WO2006111495
- Altana Pharma AG. WO2006111495; 2006
- (2006)

54
- 85018918021
- WO2005107749
- Altana Pharma AG. WO2005107749; 2005
- (2005)

55
- 85018890567
- WO2005030212
- GlaxoSmithKline. WO2005030212; 2005
- (2005)

56
- 85018862947
- WO2007107499
- GlaxoSmithKline. WO2007107499; 2007
- (2007)

57
- 60449108070
- Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration
- Lunniss CJ, Cooper AWJ, Eldred CD, Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett 2009; 19: 1380 - 5
- (2009) Bioorg Med Chem Lett , vol.19 , pp. 1380-1385
- Lunniss, C.J.¹ Cooper, A.W.J.² Eldred, C.D.³

58
- 68349150615
- Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration
- published online 9 April 2009, doi: 10.1016/j.bmcl.2009.04.012
- Woodrow MD, Ballantine SP, Barker MD, Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Bioorg Med Chem Lett 2009; published online 9 April 2009, doi: 10.1016/j.bmcl.2009.04.012
- (2009) Bioorg Med Chem Lett
- Woodrow, M.D.¹ Ballantine, S.P.² Barker, M.D.³

59
- 85018874019
- WO2005030725
- GlaxoSmithKline. WO2005030725; 2005
- (2005)

60
- 85018920866
- WO2006053784
- GlaxoSmithKline. WO2006053784; 2006
- (2006)

61
- 85018892314
- WO2006097340
- GlaxoSmithKline. WO2006097340; 2006
- (2006)

62
- 85018919453
- WO2006089689
- GlaxoSmithKline. WO2006089689; 2006
- (2006)

63
- 85018885110
- WO2007045861
- GlaxoSmithKline. WO2007045861; 2007
- (2007)

64
- 85018921715
- WO2005058892
- GlaxoSmithKline. WO2005058892; 2005
- (2005)

65
- 85018915400
- WO2005090348
- GlaxoSmithKline. WO2005090348; 2005
- (2005)

66
- 85018935243
- WO2005090353
- GlaxoSmithKline. WO2005090353; 2005
- (2005)

67
- 85018920811
- WO2005090354
- GlaxoSmithKline. WO2005090354; 2005
- (2005)

68
- 85018886493
- WO2005090352
- GlaxoSmithKline. WO2005090352; 2005
- (2005)

69
- 85018933244
- WO2007036733
- GlaxoSmithKline. WO2007036733; 2007
- (2007)

70
- 85018906419
- WO2007036734
- GlaxoSmithKline. WO2007036734; 2007
- (2007)

71
- 85018859914
- WO2008015416
- GlaxoSmithKline. WO2008015416; 2008
- (2008)

72
- 85018911489
- WO2008015437
- GlaxoSmithKline. WO2008015437; 2008
- (2008)

73
- 85018913266
- WO2008009735
- GlaxoSmithKline. WO2008009735; 2008
- (2008)

74
- 47149103616
- Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors
- Hamblin JN, Angell TDR, Ballantine SP, Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 2008; 18: 4237 - 41
- (2008) Bioorg Med Chem Lett , vol.18 , pp. 4237-4241
- Hamblin, J.N.¹ Angell, T.D.R.² Ballantine, S.P.³

75
- 85018932600
- WO2005009965
- Pfizer. WO2005009965; 2005
- (2005)

76
- 85018894239
- WO2005009966
- Pfizer. WO2005009966; 2005
- (2005)

77
- 85018904295
- US2005026952
- Pfizer. US2005026952; 2005
- (2005)

78
- 85018890203
- US2005020626
- Pfizer. US2005020626; 2005
- (2005)

79
- 85018893599
- US2005020587
- Pfizer. US2005020587; 2005
- (2005)

80
- 85018901754
- US2005020639
- Pfizer. US2005020639; 2005
- (2005)

81
- 85018890071
- Mathias J. Structure based design of PDE4 inhibitors as potential inhaled anti-inflammatories. SCI Meeting Respiratory Disease: Progress in Medicinal Chemistry, London; 2008
- (2008) Structure based design of PDE4 inhibitors as potential inhaled anti-inflammatories. SCI Meeting Respiratory Disease: Progress in Medicinal Chemistry, London
- Mathias, J.¹

82
- 85018878086
- US2005020611
- Pfizer. US2005020611; 2005
- (2005)

83
- 85018883457
- WO2006077497
- Pfizer. WO2006077497; 2006
- (2006)

84
- 85018908195
- WO2005007138
- Pfizer. WO2005007138; 2005
- (2005)

85
- 85018894607
- US2006116370
- Boehringer Ingelheim. US2006116370; 2006
- (2006)

86
- 85018918926
- US2006116371
- Boehringer Ingelheim. US2006116371; 2006
- (2006)

87
- 85018884162
- US2006116372
- Boehringer Ingelheim. US2006116372; 2006
- (2006)

88
- 85018860092
- US2006116373
- Boehringer Ingelheim. US2006116373; 2006
- (2006)

89
- 85018864067
- WO2007135026
- Boehringer Ingelheim. WO2007135026; 2007
- (2007)

90
- 85018884298
- WO2007135027
- Boehringer Ingelheim. WO2007135027; 2007
- (2007)

91
- 85018898856
- WO2007014838
- Boehringer Ingelheim. WO2007014838; 2007
- (2007)

92
- 85018931354
- WO2006111549
- Boehringer Ingelheim. WO2006111549; 2006
- (2006)

93
- 85018862972
- US2007259846
- Boehringer Ingelheim. US2007259846; 2007
- (2007)

94
- 85018920037
- EP1847543
- Boehringer Ingelheim. EP1847543; 2007
- (2007)

95
- 85018921736
- WO2009050236
- Boehringer Ingelheim. WO2009050236; 2009
- (2009)

96
- 85018920248
- WO2009050242
- Boehringer Ingelheim. WO2009050242; 2009
- (2009)

97
- 85018866485
- WO2009050248
- Boehringer Ingelheim. WO2009050248; 2009
- (2009)

98
- 85018899507
- WO2009053268
- Boehringer Ingelheim. WO2009053268; 2009
- (2009)

99
- 85018897475
- WO2009052138
- Boehringer Ingelheim. WO2009052138; 2009
- (2009)

100
- 85018885264
- WO2006114371
- Boehringer Ingelheim. WO2006114371; 2006
- (2006)

101
- 85018932081
- WO2007004958
- AstraZeneca. WO2007004958; 2007
- (2007)

102
- 85018881925
- WO2007108750
- AstraZeneca. WO2007108750; 2007
- (2007)

103
- 85018863443
- WO2008084223
- AstraZeneca. WO2008084223; 2008
- (2008)

104
- 85018898051
- WO2008084240
- AstraZeneca. WO2008084240; 2008
- (2008)

105
- 85018879905
- WO2008084236
- AstraZeneca. WO2008084236; 2008
- (2008)

106
- 85018900634
- WO2007040435
- AstraZeneca. WO2007040435; 2007
- (2007)

107
- 85018863427
- WO2005051931
- Ranbaxy. WO2005051931; 2005
- (2005)

108
- 85018907326
- EP1840123
- Ranbaxy. EP1840123; 2007
- (2007)

109
- 85018885100
- WO2005021515
- Ranbaxy. WO2005021515; 2005
- (2005)

110
- 85018901309
- WO2005026095
- Ranbaxy. WO2005026095; 2005
- (2005)

111
- 85018883302
- WO2006085212
- Ranbaxy. WO2006085212; 2006
- (2006)

112
- 85018897906
- WO2006117653
- Ranbaxy. WO2006117653; 2006
- (2006)

113
- 85018883806
- US2008009535
- Ranbaxy. US2008009535; 2008
- (2008)

114
- 85018895060
- WO2008035315
- Ranbaxy. WO2008035315; 2008
- (2008)

115
- 85018908647
- WO2008035316
- Ranbaxy. WO2008035316; 2008
- (2008)

116
- 85018919579
- WO2006129158
- Ranbaxy. WO2006129158; 2006
- (2006)

117
- 85018911930
- WO2007029077
- Ranbaxy. WO2007029077; 2007
- (2007)

118
- 85018866139
- WO2007031838
- Ranbaxy. WO2007031838; 2007
- (2007)

119
- 85018911144
- WO2007031977
- Ranbaxy. WO2007031977; 2007
- (2007)

120
- 85018908408
- WO2007045980
- Ranbaxy. WO2007045980; 2007
- (2007)

121
- 85018927298
- WO2008111009
- Ranbaxy. WO2008111009; 2008
- (2008)

122
- 85018928030
- WO2008111010
- Ranbaxy. WO2008111010; 2008
- (2008)

123
- 85018927396
- WO2007046022
- Ranbaxy. WO2007046022; 2007
- (2007)

124
- 85018887391
- EP1958947
- Ranbaxy. EP1958947; 2008
- (2008)

125
- 85018918489
- WO2005046592
- Celgene. WO2005046592; 2005
- (2005)

126
- 85018893424
- US2005239867
- Celgene. US2005239867; 2005
- (2005)

127
- 85018921034
- US2006025457
- Celgene. US2006025457; 2006
- (2006)

128
- 85018929703
- US20080234359
- Celgene. US20080234359; 2008
- (2008)

129
- 85018915286
- WO2006025991
- Celgene. WO2006025991; 2006
- (2006)

130
- 85018923536
- WO2005110085
- Celgene. WO2005110085; 2005
- (2005)

131
- 85018907767
- US2009010886
- Celgene. US2009010886; 2009
- (2009)

132
- 85018864557
- WO200800659
- Chiesi Farmaceutici SPA. WO200800659; 2008
- (2008)

133
- 85018862934
- WO2009018909;
- Chiesi Farmaceutici SPA. WO2009018909; 2009
- (2009)

134
- 85018870388
- WO2006095666
- Kyorin. WO2006095666; 2006
- (2006)

135
- 85018862785
- WO2008029882
- Kyorin. WO2008029882; 2008
- (2008)

136
- 85018899186
- WO2008156094
- Kyorin. WO2008156094; 2008
- (2008)

137
- 85018883669
- WO2008156102
- Kyorin. WO2008156102; 2008
- (2008)

138
- 85018928455
- JP2009040711
- Kyorin. JP2009040711; 2009
- (2009)

139
- 85018860672
- WO2008029829
- Kyorin. WO2008029829; 2008
- (2008)

140
- 85018919987
- WO2008129624
- Kyorin. WO2008129624; 2008
- (2008)

141
- 85018860182
- JP2005015354
- Kyowa Hakko. JP2005015354; 2005
- (2005)

142
- 85018913808
- JP2005060375
- Kyowa Hakko. JP2005060375; 2005
- (2005)

143
- 85018927008
- JP2005060376
- Kyowa Hakko. JP2005060376; 2005
- (2005)

144
- 85018934548
- WO2005087749
- Kyowa Hakko. WO2005087749; 2005
- (2005)

145
- 85018909969
- WO2004069831
- Glenmark Pharmaceuticals SA. WO2004069831; 2004
- (2004)

146
- 85018927358
- WO2004111044
- Glenmark Pharmaceuticals SA. WO2004111044; 2004
- (2004)

147
- 85018919059
- WO2006051390l
- Glenmark Pharmaceuticals SA. WO2006051390l; 2006
- (2006)

148
- 85018913017
- WO2006011024
- Glenmark Pharmaceuticals SA. WO2006011024; 2006
- (2006)

149
- 85018861637
- WO2006064355
- Glenmark Pharmaceuticals SA. WO2006064355; 2006
- (2006)

150
- 85018920221
- WO2006040650
- Glenmark Pharmaceuticals SA. WO2006040650; 2006
- (2006)

151
- 85018916937
- WO2006010567
- Curacyte Discovery GmbH. WO2006010567; 2006
- (2006)

152
- 85018914782
- EP1619196
- Curacyte Discovery GmbH. EP1619196; 2006
- (2006)

153
- 85018923602
- WO2008032171
- Matrix Laboratories. WO2008032171; 2008
- (2008)

154
- 85018900111
- WO2005061458
- Memory Pharmaceuticals Corporation. WO2005061458; 2005
- (2005)

155
- 85018888654
- WO2006135828
- Memory Pharmaceuticals Corporation. WO2006135828; 2006
- (2006)

156
- 85018886993
- WO2006044528
- Memory Pharmaceuticals Corporation. WO2006044528; 2006
- (2006)

157
- 85018901728
- WO2007123953
- Memory Pharmaceuticals Corporation. WO2007123953; 2007
- (2007)

158
- 85018908935
- WO2006044955
- Memory Pharmaceuticals Corporation. WO2006044955; 2006
- (2006)

159
- 85018919747
- WO2005111007
- Otsuka Pharmaceutical Company Ltd. WO2005111007; 2005
- (2005)

160
- 85018891248
- WO2007058338
- Otsuka Pharmaceutical Company Ltd. WO2007058338; 2007
- (2007)

161
- 85018875576
- WO2007148806
- Otsuka Pharmaceutical Company Ltd. WO2007148806; 2007
- (2007)

162
- 85018936470
- WO2008104175
- Leo Pharma A/S. WO2008104175; 2008
- (2008)

163
- 85018873490
- WO2008077404
- Leo Pharma A/S. WO2008077404; 2008
- (2008)

164
- 85018906220
- WO2008125111
- Leo Pharma A/S. WO2008125111; 2008
- (2008)

165
- 85018925847
- WO2006026754
- Plexxikon Inc. WO2006026754; 2006
- (2006)

166
- 85018878043
- US2006041006
- Plexxikon Inc. US2006041006; 2006
- (2006)

167
- 85018923203
- WO2005028471
- Schering Corp. WO2005028471; 2005
- (2005)

168
- 85018867806
- WO2005116009
- Schering Corp. WO2005116009; 2005
- (2005)

169
- 85018894546
- WO2008021235
- Schering Corp. WO2008021235; 2008
- (2008)

170
- 85018918882
- WO2008008327
- Schering Corp. WO2008008327; 2008
- (2008)

171
- 85018870798
- WO2009009002
- Schering Corp. WO2009009002; 2009
- (2009)

172
- 85018884063
- WO2009009003l
- Schering Corp. WO2009009003l; 2009
- (2009)

173
- 85018902635
- WO2005049581
- Almirall SA. WO2005049581; 2005
- (2005)
- Almirall, S.A.¹

174
- 85018926171
- WO2005123692
- Almirall SA. WO2005123692; 2005
- (2005)
- Almirall, S.A.¹

175
- 85018863668
- WO2005123693
- Almirall SA. WO2005123693; 2005
- (2005)
- Almirall, S.A.¹

176
- 85018871397
- WO2006058723
- Almirall SA. WO2006058723; 2006
- (2006)
- Almirall, S.A.¹

177
- 85018878584
- WO2006058724
- Almirall SA. WO2006058724; 2006
- (2006)
- Almirall, S.A.¹

178
- 85018879081
- WO2007017078
- Almirall SA. WO2007017078; 2007
- (2007)
- Almirall, S.A.¹

179
- 33644658285
- Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity
- Dietsch GN, Dipalma CR, Eyre RJ, Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 2006; 34 (1): 39 - 51
- (2006) Toxicol Pathol , vol.34 , Issue.1 , pp. 39-51
- Dietsch, G.N.¹ Dipalma, C.R.² Eyre, R.J.³

180
- 2542487257
- The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys
- Losco PE, Evans EW, Barat SA, The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol Pathol 2004; 32 (3): 295 - 308
- (2004) Toxicol Pathol , vol.32 , Issue.3 , pp. 295-308
- Losco, P.E.¹ Evans, E.W.² Barat, S.A.³

181
- 44149083490
- Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog
- Hanton G, Sobry C, Daguès N, Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol Lett 2008; 179 (1): 15 - 22
- (2008) Toxicol Lett , vol.179 , Issue.1 , pp. 15-22
- Hanton, G.¹ Sobry, C.² Daguès, N.³

182
- 85018894337
- Available from [Last accessed 1 September 2009]
- Article in “The Independent”. Available from: http://www.independent.co.uk/news/business/news/trials-on-celltechs-asthma-drug-halted-595688.html. [Last accessed 1 September 2009]

183
- 52949103280
- Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?
- Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008; 155: 288 - 90
- (2008) Br J Pharmacol , vol.155 , pp. 288-290
- Giembycz, M.A.¹

184
- 85018898519
- A service of the US National Institutes of Health. Search of GW842470X. Available from [Last accessed 21 July 2009]
- Clinical trials.gov. A service of the US National Institutes of Health. Search of GW842470X. Available from: http://clinicaltrials.gov/ct2/results?intr=%22GW842470X+cream%22. [Last accessed 21 July 2009]

185
- 33846455467
- SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase
- Duplantier AJ, Bachert EL, Cheng JB, SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem 2007; 50: 344 - 9
- (2007) J Med Chem , vol.50 , pp. 344-349
- Duplantier, A.J.¹ Bachert, E.L.² Cheng, J.B.³

186
- 35948942231
- A randomized, double-blind, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with persistent asthma
- Danto S, Wei GC, Gill J, A randomized, double-blind, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with persistent asthma. Am J Respir Crit Care Med 2007; 175: A485
- (2007) Am J Respir Crit Care Med , vol.175 , pp. A485
- Danto, S.¹ Wei, G.C.² Gill, J.³

187
- 35948942231
- A randomized, double-blind, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD
- Danto S, Wei GC, Gill J, A randomized, double-blind, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD. Am J Respir Crit Care Med 2007; 175: A131
- (2007) Am J Respir Crit Care Med , vol.175 , pp. A131
- Danto, S.¹ Wei, G.C.² Gill, J.³

188
- 62849125720
- UK-500,001, a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNFalpha, MIP1beta and LTA4 release from native human blood cells
- Trevethick M, Banner K, Ballard S, UK-500,001, a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNFalpha, MIP1beta and LTA4 release from native human blood cells. Am J Respir Crit Care Med 2007; 175: A116
- (2007) Am J Respir Crit Care Med , vol.175 , pp. A116
- Trevethick, M.¹ Banner, K.² Ballard, S.³

189
- 66749083578
- In vivo profile of intratracheally delivered phosphodiesterase type 4 (PDE4) inhibitor UK-500,001- inhibits bronchoconstriction and inflammation
- Trevethick M, Philip J, Chaffe P, In vivo profile of intratracheally delivered phosphodiesterase type 4 (PDE4) inhibitor UK-500,001- inhibits bronchoconstriction and inflammation. Am J Respir Crit Care Med 2007; 175: A927
- (2007) Am J Respir Crit Care Med , vol.175 , pp. A927
- Trevethick, M.¹ Philip, J.² Chaffe, P.³

190
- 52949086110
- The PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine [abstract 2964]
- Philipps P, Bennetts M, Banner K, The PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine [abstract 2964]. Eur Res J 2007: 491s
- (2007) Eur Res J , pp. 491s
- Philipps, P.¹ Bennetts, M.² Banner, K.³

191
- 66749187721
- A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
- Vestbo J, Tan L, Atkinson G, A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Res J 2009; 33: 1039 - 44
- (2009) Eur Res J , vol.33 , pp. 1039-1044
- Vestbo, J.¹ Tan, L.² Atkinson, G.³

192
- 77955272058
- In vitro characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration
- Knowles RG, Tralau-Stewart C, Dawson J, In vitro characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration. Am J Respir Crit Care Med 2009; 179: A4581
- (2009) Am J Respir Crit Care Med , vol.179 , pp. A4581
- Knowles, R.G.¹ Tralau-Stewart, C.² Dawson, J.³

193
- 77955273331
- In vivo characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration
- Knowles RG, Ball DI, Gascoigne MH, In vivo characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration. Am J Respir Crit Care Med 2009; 179: A4582
- (2009) Am J Respir Crit Care Med , vol.179 , pp. A4582
- Knowles, R.G.¹ Ball, D.I.² Gascoigne, M.H.³

194
- 85018877269
- The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics
- Singh D, Cass L, Pétavy F, The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics. Eur Res J 2008; 32: 2732
- (2008) Eur Res J , vol.32 , pp. 2732
- Singh, D.¹ Cass, L.² Pétavy, F.³

195
- 33745939122
- The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
- Boswell-Smith V, Spina D, Oxford AW, The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther 2006; 318: 840 - 8
- (2006) J Pharmacol Exp Ther , vol.318 , pp. 840-848
- Boswell-Smith, V.¹ Spina, D.² Oxford, A.W.³

196
- 85018891557
- Available from [Last accessed 14 July 2009]
- Anacore pipeline overview: AN2728. Available from: http://www.anacor.com/an2728.php. [Last accessed 14 July 2009]

197
- 85018924876
- Available from [Last accessed 14 July 2009]
- Santen: Research and Development. Available from: http://www.santen.com/ir/reports/ar2008_07.pdf. [Last accessed 14 July 2009]

198
- 26244467287
- Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias
- Erratum in: Cell 2005;123:535-6
- Lehnart SE, Wehrens XH, Reiken S, Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123 (1): 25 - 35, Erratum in: Cell 2005;123:535-6
- (2005) Cell , vol.123 , Issue.1 , pp. 25-35
- Lehnart, S.E.¹ Wehrens, X.H.² Reiken, S.³

199
- 0036790480
- Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis
- Robichaud A, Stamatiou PB, Jin SL, Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045 - 52
- (2002) J Clin Invest , vol.110 , pp. 1045-1052
- Robichaud, A.¹ Stamatiou, P.B.² Jin, S.L.³

200
- 0034625541
- Atomic Structure of PDE4: Insights into phosphodiesterase mechanism and specificity
- Xu RX, Hassel AM, Vanderwall D, Atomic Structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science 2000; 288: 1822 - 5
- (2000) Science , vol.288 , pp. 1822-1825
- Xu, R.X.¹ Hassel, A.M.² Vanderwall, D.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.